Fredag 4 April | 17:37:35 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-27 18:00 Bokslutskommuniké 2025
2025-11-27 18:00 Kvartalsrapport 2025-Q3
2025-08-28 18:00 Kvartalsrapport 2025-Q2
2025-06-05 N/A X-dag ordinarie utdelning INT 0.00 SEK
2025-06-04 N/A Årsstämma
2025-05-27 18:00 Kvartalsrapport 2025-Q1
2025-02-28 - Bokslutskommuniké 2024
2024-11-28 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-27 - X-dag ordinarie utdelning INT 0.00 SEK
2024-05-24 - Årsstämma
2024-04-30 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-09-25 - Extra Bolagsstämma 2023
2023-08-24 - Kvartalsrapport 2023-Q2
2023-06-07 - Kvartalsrapport 2023-Q1
2023-05-12 - X-dag ordinarie utdelning INT 0.00 SEK
2023-05-11 - Årsstämma
2023-03-02 - Bokslutskommuniké 2022
2023-01-30 - Extra Bolagsstämma 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-08 - Kvartalsrapport 2022-Q1
2022-05-13 - X-dag ordinarie utdelning INT 0.00 SEK
2022-05-12 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-12-23 - Extra Bolagsstämma 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Intellego Technologies är verksamt inom fotokrom indikatorteknik. Bolaget levererar fotokroma bläck som utformar visuella indikatorer som gör det möjligt att se effekterna av osynligt ultraviolett ljus. Bläcket ändrar färg baserat på exponering för ultraviolett bestrålning eller specifika ämnen. Produkterna används primärt av OEM-tillverkare och används i branschapplikationer runt om i världen. Intellego Technologies grundades 2011 och har sitt huvudkontor i Stockholm.
2025-03-21 11:01:00

Due to a positive reception on the dosimeter products, Intellego and Likang have agreed speed up the deliveries for the Chinese market but also to expand its collaboration to cover additional markets healthcare markets, outside of China. Intellego has granted the exclusive sales and marketing right for two UVC disinfection product used in the healthcare market in Japan, South Korea, Singapore, Thailand, Indonesia and Malaysia, which is connected to the minimum volumes of 360 million USD. The amount might be higher depending on which product mix that is sold.

The deal is dependent on market approval from regulatory agencies and other standard terms such as product quality. The parties do not foresee any significant regulatory obstacle as the product has a low-risk classification and majority of documentation is already in place. The volumes will be reached over a five-year time period with scaling volumes over time. Sales launch is expected to take place in 2025 which is when the first revenue from this project is expected."
 
Zhongyou Medical (Likang) is a wholly owned subsidiary of Jiangsu Yuyue Medical Equipment and Supply Co., Ltd, which is listed on the Shenzhen Stock market, a leading distributor of a variety of disinfectant products into more than 3000 hospitals in China nationally.
 
Yuwell medical, with full name of Jiangsu Yuyue Medical Equipment and Supply Co., Ltd. has established 12 R&D centers and 9 production bases in Shanghai, Shenzhen, Nanjing, Suzhou, Danyang, Tibet, the Netherlands, Germany, Italy, and other places, forming a complete global R&D, production, marketing, and service network that serves more than 300,000 medical institutions worldwide and covers 131 countries and regions, benefitting 300 million households around the world. https://www.yuwell.com/